Seojin Moon

Seojin Moon

Auto-generated profile, based on publicly available information

Seojin Moon

Department of Otorhinolaryngology Yonsei University College of Medicine Seoul Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2025 in Allergy
Verified
Journal Article
Open access
SMSeojin Moon
Seojin Moon
SMSungmin Moon
Sungmin Moon
SLSol Lee
Sol Lee
GKGyeongyeob Kim
Gyeongyeob Kim
MKMin‐Seok Koo
Min‐Seok Koo
MRMin-Seok Rha
Min-Seok Rha
Background: As treatment responses differ according to the inflammatory endotype of chronic rhinosinusitis (CRS), identifying the endotype could facilitate personalized treatment. We aimed to identify a noninvasive epithelial lining fluid (ELF) biomarker for the type 2 (T2) endotype of CRS.Methods: Nasal tissue and ELF samples were obtained from patients with CRS and control individuals. Single‐cell RNA sequencing (scRNA‐seq) data were analyzed. The expression of inflammatory mediators was measured using Luminex multiplex assays and enzyme‐linked immunosorbent assays.Results: Analysis of the scRNA‐seq data revealed that CST1 was exclusively expressed in epithelial cells of T2 CRS, but not in those of non‐T2 CRS, and this was confirmed by immunofluorescence staining. Cystatin SN expression was detected in ELF, and its levels were significantly higher in T2 CRS than in non‐T2 CRS and controls. The expression level of cystatin SN in the ELF was positively correlated with the Lund‐Mackay CT, SNOT‐22, and JESREC scores, whereas it was inversely correlated with olfactory function. Furthermore, ELF cystatin SN levels correlated with the tissue/blood eosinophil count and nasal tissue expression of T2 inflammatory mediators, indicating that ELF cystatin SN is a reliable marker of nasal T2 inflammation. In the receiver operating characteristics curve analysis evaluating the predictive efficacy for T2 CRS, the AUC for ELF cystatin SN was 0.894 (0.936 in the validation cohort), which was higher than that of other markers, including blood eosinophil count, serum total IgE level, and the JESREC score. With a cut‐off value of 112.5 ng/mg, ELF cystatin SN yielded a 75.0% sensitivity and 92.0% specificity.Conclusions: ELF cystatin SN is a clinically feasible, noninvasive biomarker with superior accuracy for predicting T2 CRS.

10 July 2022 in Journal of Audiology and Otology
Verified
Journal Article
Open access
PDF file
SMSeojin Moon
Seojin Moon
YLYujin Lee
Yujin Lee
JJJinsei Jung
Jinsei Jung
In Seok MoonIn Seok Moon
In Seok Moon
SBSeong Hoon Bae
Seong Hoon Bae
Background and Objectives: We investigated the clinical validity of and correlation between the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores and the eustachian tube function test (ETFT) results in patients with a normal drum. Subjects and Methods: The study included 49 patients (93 ears) with unilateral or bilateral ear fullness over >3 months. All patients were administered the ETDQ-7 survey and underwent the ETFT on the same day. The receiver operating characteristic (ROC) curve and the association between the results were statistically analyzed. Results: ETDQ-7 scores were not significantly correlated with the ETFT results or with middle ear pressure. ETDQ-7 scores in patients with eustachian tube dysfunction (ETD) were significantly higher than those in patients with normal ETFT results (p=0.039) when ETD was defined as a pressure change <10 daPa on the ETFT. The area under the ROC curve was 0.631, with a sensitivity of 37.0% and specificity of 89.4%. Conclusions: The ETDQ-7 has limited clinical significance in patients with ETD but a normal drum. Therefore, concomitant objective tests should be performed to diagnose patients with ETD.

14 January 2024 in Head & Neck
Verified
Journal Article
Closed access
PMPiero Giuseppe Meliante
Piero Giuseppe Meliante
LBLudovica Battilocchi
Ludovica Battilocchi
ACAndrea Costantino
Andrea Costantino
KLKyuin Lee
Kyuin Lee
SMSeo Jin Moon
Seo Jin Moon
SKSe‐Heon Kim
Se‐Heon Kim

21 February 2023 in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
SMSeoJin Moon
SeoJin Moon
In Seok MoonIn Seok Moon
In Seok Moon
Various types of bone conduction hearing aids have been widely used for hearing rehabilitation for the last 30 years. Among them, the recently launched Osia®2 system is a new active transcutaneous bone conduction implant system using piezoelectric effect. This can be expected to deliver more efficient sound transmission, overcome sound attenuation, and improve high-frequency hearing than conventional passive transcutaneous hearing aids, and is considered to be cosmetically superior to percutaneous hearing aids. Recently, we experienced two cases of Osia®2 implantation in patients with iatrogenic unilateral hearing loss. Both patients showed improved pure tone threshold and better Korean Hearing in Noise Test (K-HINT) score after implantation. Furthermore, all of them had no complications after Osia®2 implantation.

30 November 2024 in Journal of Rhinology
Verified
Journal Article
Open access
PDF file
SMSeojin Moon
Seojin Moon
YJYeonsu Jeong
Yeonsu Jeong
MRMin-Seok Rha
Min-Seok Rha
CKChang-Hoon Kim
Chang-Hoon Kim
HCHyung-Ju Cho
Hyung-Ju Cho
Background and Objectives: Congenital choanal atresia is a rare condition that occurs in approximately 1 in 7,000 to 8,000 live births and involves the obstruction of the posterior nasal airway. It may present as either unilateral or bilateral, with bilateral cases being more severe due to the risk of immediate neonatal respiratory distress. Bilateral congenital choanal atresia (BCCA) necessitates prompt medical intervention to prevent cyanosis and significant breathing difficulties. This study focuses on the timing of surgery, the duration of stent use, and postoperative care in patients with bilateral congenital choanal atresia who underwent endoscopic transnasal surgery. Unlike previous studies, this research emphasizes the efficacy of an extended stenting period and introduces novel stenting techniques aimed at reducing restenosis.Methods: From 2018 to 2021, three patients with BCCA underwent transnasal surgery that included the placement of stents. We retrospectively analyzed their medical records, focusing on the surgical outcomes in relation to the duration of stent placement and postoperative care. A novel approach was adopted, involving the use of customized stent sizes tailored to the specific anatomical factors of each patient, which facilitated improved neochoana maintenance.Results: The average interval from diagnosis to surgery was 3.6 weeks. Surgery was successful in all cases, and the stent was removed after 6 months. In all patients, stable neochoanae were maintained without significant restenosis. Additionally, we observed that maintaining a stent for a period longer than previously recommended significantly reduced the risk of restenosis compared to the shorter durations used in earlier studies.Conclusion: Our study suggests that an extended stenting period of 6 months or more is crucial for maintaining long-term patency in patients with BCCA. This approach could lead to a more reliable stenting protocol and improved postoperative care, potentially establishing a new standard for managing BCCA.